Janssen and BMS to Test Darzalex, Opdivo Combo in Multiple Myeloma and Solid Tumors
Janssen Biotech and Bristol-Myers Squibb will collaborate in a clinical trial program to evaluate the combination of Darzalex (daratumumab) and Opdivo (nivolumab) in multiple myeloma patients and in several solid tumors in Phase 1b and Phase 2 trials. Darzalex and Opdivo are two immunotherapy agents that are meant to boost…